This Amylyx Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

• UBS analyst Marcus Cole initiated coverage on Amrize Ltd (NYSE:AMRZ) with a Neutral rating and announced a price target of $53. Amrize shares closed at $51.99 on Monday. See how other analysts view this stock.
• Rosenblatt analyst Chris Brendler initiated coverage on Galaxy Digital (NASDAQ:GLXY) with a Buy rating and announced a price target of $25. Galaxy Digital shares closed at $18.47 on Monday. See how other analysts view this stock.
• Guggenheim analyst Seamus Fernandez initiated coverage on Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) with a Buy rating and announced a price target of $17. Amylyx Pharmaceuticals shares closed at $5.02 on Monday. See how other analysts view this stock.
• Jefferies analyst Maury Raycroft initiated coverage on Cardiff Oncology, Inc. (NASDAQ:CRDF) with a Hold rating and announced a price target of $3.5. Cardiff Oncology shares closed at $3.16 on Monday. See how other analysts view this stock.

Considering buying AMLX stock? Here’s what analysts think:

Read This Next:

• BlackBerry Gears Up For Q1 Print; Here Are The Recent Forecast Changes From Wall Street’s Most Accurate Analysts

Photo via Shutterstock